cyrilzakka/clinical-trials huggingface dataset:
The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis

The goal of this clinical trial is to evaluate whether Shan Shang Water (hydrogen ion water) can help treat allergic rhinitis in adults and affect immune markers.

Does Shan Shang Water reduce allergic rhinitis symptoms? What changes occur in immune markers when using Shan Shang Water? Researchers will compare Shan Shang Water to a placebo (an inactive substance) to see if it effectively treats allergic rhinitis.

Participants will:

Take Shan Shang Water or a placebo every day for 24 weeks. Visit the clinic every four weeks for checkups and tests. Record symptoms in a diary, noting things like sneezing, nasal congestion, and any use of medication.

The goal of this clinical trial is to evaluate whether Shan Shang Water (hydrogen ion water) can help treat allergic rhinitis in adults and affect immune markers. The main questions the study aims to answer are:

Does Shan Shang Water reduce allergic rhinitis symptoms? What changes occur in immune markers when using Shan Shang Water? Researchers will compare Shan Shang Water to a placebo (an inactive substance) to see if it effectively treats allergic rhinitis.

Participants will:

Take Shan Shang Water or a placebo every day for 24 weeks. Dosage: 660 ml of Shan Shang Water (or placebo) three times a day-morning, noon, and evening.

Drink 30 minutes before meals or when thirsty. Avoid drinking 30 minutes before or after meals and before or after brushing teeth with toothpaste.

Control Group:

The control group will drink 1,500-2,000 ml of water daily, following their normal routine.

Visit Schedule:

Participants will visit the clinic every 4 weeks for checkups and tests. Participants will also keep a daily diary to track their symptoms, including sneezing, nasal congestion, runny nose, and any medication use.

Expected Results:

Symptom Improvement:

The investigators will assess the reduction in allergic rhinitis symptoms (sneezing, nasal congestion, runny nose, and itching).

Immune Response:

The investigators will monitor immune markers like IgE levels and eosinophil counts every 3 months.

Conclusion:

This trial will determine if Shan Shang Water can be an effective treatment for allergic rhinitis by reducing symptoms and affecting immune markers. The results will provide valuable insights into its potential use as a non-pharmacological treatment option for allergic rhinitis.

Eligibility Criteria:
Inclusion Criteria:

* Intermittent or persistent recurrent bouts of sneezing, watery nose, itchy and stuffy nose may be accompanied by eye symptoms including itchy, watery eyes, red and burning eyes, with or without wheezing, coughing, shortness of breath and chest tightness shape.
* The symptoms are more severe or severe, and have a significant impact on quality of life.

Exclusion Criteria:

* Pregnant women and parturients.
* Patients with liver, kidney and heart disease.
* Patients with past or current tumors.
* Specific immunotherapy, biologics, or small molecule drug therapy is planned or initiated.
The Effect of Binaural Beats on Pain Perception and Analgesic Medication Use in Patients Suffering From Chronic Pain

This study evaluates the effect of binaural beats on pain perception and subsequent need for analgesic medication use in patients suffering from diseases causing chronic pain. All patients will receive two consecutive interventions: binaural beat signals embedded in relaxing music and placebo (relaxing music without the binaural beat component), in random order.

Binaural beats consist of two artificially produced sound waves, differing in wave frequency, presented simultaneously and separately to each ear. The brain, following binaural beat processing, synchronizes to the frequency difference between the two waves. Therefore, using a 5 Hz frequency difference (theta rhythm), which promotes relaxation, we could alleviate pain perception and subsequent analgesic medication use.

Patients suffering from chronic pain will receive two consecutive interventions: binaural beat signals embedded in relaxing music and placebo (relaxing music without the binaural beat component), in random order.

Electroencephalogram (EEG) recordings will be used to confirm brain frequency synchronization, whereas pain severity scales and a diary recording analgesic medication use will be used to identify differences between intervention and placebo arms.

Eligibility Criteria:
Inclusion Criteria:

* Chronic pain
* Regular analgesic medication use

Exclusion Criteria:

* Malignant pain
* Headache as the cause of chronic pain
* Hearing disability
* Neuropsychiatric disease
* Previous experience with binaural beats
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to celecoxib, the feasibility of performing six different molecular assays by qRTPCR on formalin fixed paraffin embedded tissue obtained from breast cancer core biopsies and breast cancer reexcision patients, to assess change in Ki-67, PCNA, and several other markers by qRTPCR, correlate change in expression of Ki-67, PCNA, CAX-2, and bcl-2, measured by immunohistochemistry to change measured by qRTPCR, and to determine the reliability of the qRTPCR and immunohistochemical assays by performed selected assays on the same tissue in two different institutions

Eligibility Criteria:
Inclusion Criteria:

* women with a recent diagnosis of T1 or T2 noninvasive breast cancer by large core needle or excisional biopsy
* confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post diagnostic analyses to perform research assessments
* reexcision planned within 10 days to 6 weeks from study start

Exclusion Criteria:

* no hormone replacement therapy within 90 days prior to biopsy
* no history of asthma, allergy ASA, NSAIDS, celecoxib of other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study
* no celecoxib or rofecoxib use within one month of biopsy
* no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
* no current anticoagulants
* no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study
* no aromatase inhibitor in the six months prior to participation
* no concomitant lithium
* no known significant bleeding disorder
Stargardt Disease in Childhood

Retrospective chart review study to elucidate the phenotype and genotype of children with ABCA4-associated Stargardt disease.


Eligibility Criteria:
Inclusion Criteria:

* genetically confirmed ABCA4-associated inherited retinal dystrophy

Exclusion Criteria:

* 18 years old and older
Study of BCMA CAR-T in Multiple Myeloma

The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.


Eligibility Criteria:
Inclusion Criteria:

* 1. 18 years to 70 years, expected survival \> 3 months;
* 2. Confirmed diagnosis of active MM as defined by IMWG. BCMA expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry.
* 3. BCMA-expressing B cell malignancy must be assured and must be relapsed or refractory disease.；
* 4. ECOG performance status of 0-2;
* 5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN;
* 6. No serious allergic constitution;
* 7. No other serous diseases that conflicts with the clinical program;
* 8. No other cancer history;
* 9. female participants of reproductive potential must have a negative serum pregnancy test;
* 10. Subjects must have signed written, informed consent.

Exclusion Criteria:

* 1. Pregnant or lactating women;
* 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
* 3. Active hepatitis B or hepatitis C infection;
* 4. Recent or current use of glucocorticoid or other immunosuppressor;
* 5. serious mental disorder;
* 6. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
* 7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;
Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

This study is an open-label, active-controlled,non-inferiority trial comparing efficacy and safety of levetiracetam versus valproate in idiopathic generalized tonic-clonic epilepsy.


Eligibility Criteria:
Inclusion Criteria:

* Age≥16
* At least 2 unprovoked generalized tonic-clonic seizures in last 2 years with at least one in last 6 months
* Normal brain MRI or MRI without epileptogenic lesion
* Normal electroencephalography(EEG) or existence of generalized epileptiform discharges without any focal epileptiform discharges.
* Signing consent form

Exclusion Criteria:

* History of treatment by sodium valproate or levetiracetam
* History of treatment by any anti-epileptic drug in last 6 months
* Plan for pregnancy
* Using no certain contraceptive method
* History of past or current hepatic disease
* History of past or current renal disease
* History of past or current hematologic disease
* History of known psychiatric disease
* History of status epilepticus
Baduanjin Training for Depression and Anxiety Patients

In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.

Depression and anxiety, the two common mental health problems, are prevalent in the world. But there is a lack of sufficient no-drug intervention for relieving these two symptoms. The study focuses on mixed depressive and anxiety disorder, which symptoms are not sufficiently severe, numerous, or persistent to justify a diagnosis of depressive disorder or an anxiety disorder.

Baduanjin is a form of mind-body exercise with a profound philosophical foundation rooted in oriental culture. Previous studies have provided some evidences of beneficial effects on Baduanjin for depression and anxiety. Moreover, the effects and mechanisms of Baduanjin on patients with symptoms of depression and anxiety are yet to be further investigated.

This is a two-group prospective, randomized, assessor-blinded trial, planning to enroll 120 participants (60 for Baduanjin intervention group receiving health education plus a Baduanjin breathing training program, and 60 for health education control group only receiving health education).

The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung function.

Eligibility Criteria:
Inclusion Criteria:

* Subject with depression or anxiety symptom diagnosed by ICD-10.
* Depression 7≤HAMD-17≤29，anxiety 7≤HAMA-14≤29.
* Subject has a clear mind and the ability to read, to talk and to communicate.
* Subject agrees to participate in this study and sign to the informed consent.

Exclusion Criteria:

* Subject with bipolar disorder, psychotic disorder, organic mental disorder and cognitive disorder.
* Subject with alcohol abuse, substance dependence and suicidal behavior in past-year.
* Subject has severe somatic disease.
* Subject is pregnant or lactating women.
Preventive Effects of Ginseng Against Atherosclerosis

This study is a 12-month, double-blind, randomized, placebo-controlled trial. The purpose of this study is to determine whether ginseng is effective in the prevention of atherosclerosis and subsequent ischemic stroke. High-risk patients with severe atherosclerosis in the major intracranial arteries and extracranial carotid artery were enrolled.


Eligibility Criteria:
"Inclusion Criteria"

Patients were included if they

1. were aged 20 to 80 years;
2. had occlusion or severe stenosis (≥ 70%) of extracranial carotid artery and major intracranial arteries (intracranial carotid artery, middle cerebral artery, anterior cerebral artery, intracranial vertebral, basilar, or posterior cerebral artery) as documented by cerebral catheter angiography;
3. had any risk factor for stroke, such as hypertension, diabetes mellitus, hypercholesterolemia, smoking, alcohol drinking, or previous stroke history;
4. had no adverse reactions to administration of ginseng; and
5. agreed to participate in the trial.

"Exclusion Criteria"

Patients were excluded if they

1. did not agree to participate in the trial;
2. had any genetic cerebrovascular diseases;
3. had adverse reactions to contrast medium;
4. were pregnant or planning to be pregnant;
5. had a history of cardioembolic stroke;
6. had an emboligenic cardiac disease such as atrial fibrillation, valve disease, congestive heart failure, or recent myocardial infarction;
7. had a risk of stroke of other determined etiology according to the TOAST classification;
8. had undergone any neurointervention procedure or surgery, such as intra-arterial thrombolysis, angioplasty procedures, carotid endarterectomy, or bypass surgery;
9. had chronic kidney disease (GFR \< 30 ml/min); or
10. had severe hepatic dysfunction.
A Randomized Controlled Trial Evaluating the Effectiveness of a Salvia-based Mouthwash in Palliative Care

This study examines the effectiveness of an herbal mouthwash made from salvia in maintaining good oral health among patients in palliative care. It is hypothesized that using the mouthwash made from salvia will result in better oral health and more oral comfort than using with conventional normal saline mouthwash.

The aim of this study is to examine the effectiveness of an herbal mouthwash made from salvia officinalis (SO) in maintaining good oral health among patients in palliative care. The study compares a mouthwash based on salvia tea solution with conventional normal saline mouthwash and addresses the following research questions:

1. Does the SO-based mouthwash provide a better treatment than conventional normal saline in maintaining good oral health in terminally ill patients?
2. Is there a difference in the individual perception of oral comfort in patients receiving SO versus patients receiving saline rinsing solution?

Eligibility Criteria:
Inclusion Criteria:

* Attending bedded unit at Hospice
* Over 18 years of age and able to provide written formal consent
* Diagnosed with advanced cancer
* Patient with positive response when asked if they experience oral discomfort or complications.

Exclusion Criteria:

* Estimated life expectancy prognosis of less than 2 weeks
* Significant cognitive impairment
* Current use of antifungal medication
* Currently receiving radiation therapy or chemotherapy
* Epileptic
* Diabetic
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.


Eligibility Criteria:
Inclusion Criteria:

* Idiopathic PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank criteria
* PD stage corresponds to 4 or 5 in the 'off' state according to the modified Hoehn \& Yahr (H \& Y) classification of disease severity
* Levodopa-responsive subjects demonstrate some identifiable 'ON response' established by observation by Investigator and demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated

Exclusion Criteria:

* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
* Undergone surgery for the treatment of PD
* Contraindications to levodopa
* Subjects with any neurological deficit that may interfere with the study assessments
Effects of Exercise on the Symptoms of Premenstrual Syndrome and Dysmenorrhoea and Blood Flow of Genital Tract

Effects of exercise on the symptoms of premenstrual syndrome and dysmenorrhoea and blood flow of genital tract. Different self-reported questionnaires and vaginal ultrasound flowmetry are used in the prospective observational trial. The study has interventional and control groups. There are changes in premenstrual syndrome complaints and dysmenorrhoea complaints during the study period.The deegre of menstrual pain and self-awareness improve during the period of study. The ultrasound examination shows changes in genital blood flow after exercise.

Subject of the study:

Examination of premenstrual syndrome and dysmenorrhoea treatment results with Aviva exercise intervention.

Method of the study:

Prospective observational trial with the participation of volunteers.

Questionnaires:

1. PRISM calendar: Prospective Record of the Impact and Severity of Menstrual Symptoms (Reid, 1995). The participants have to fill out this every day,
2. The Body Awareness Questionnaire Shields, S. A., Mallory, M.E., \& Simon, A. (1989). The Body Awareness Questionnaire: Reliability and validity. Journal of Personality Assessment, 53(4), 802-815
3. Examination to measure the intensity of menstrual pain: Numeric Rating Scale
4. Heart rate monitoring and documentation before and after the exercises; completion of the Borg Scale of Perceived Exertion to measure exercise intensity;
5. Questionnaire of life style
6. Beck depression questionnaire

Ultrasound examination:

Doing the Aviva exercises, ultrasound measurements are performed in Robert Hospital (Budapest) on the patients participating in the study. The first measurement is performed for each person before starting the exercises. When the first subject has finished the exercise, a control ultrasound measurement will be carried out.

In the control group there is also twice ultrasound examination for the individuals.

Measured parameters: PI (pulsatility index) of uterine artery transvaginal ultrasound measurement followed by statistical evaluation of the results.

Eligibility Criteria:
Inclusion Criteria:

* BMI 17-35
* regular menstrual cycles (cycles of 21-35 days)
* no endocrinological disease
* no endometriosis
* no experience in Aviva aerob exercises
* symptoms of premenstrual syndrome
* symptoms of dysmenorrhoea
* Score below 40 from Beck depression questionnaire

Exclusion Criteria:

* pregnancy
* pelvic inflamatory disease (PID), secondary dysmenorrhoea
* gynecological operation
* failure to complete the questionnaire (3 consecutive days and 5 days interrupted)
* dissatisfaction with the continuation of the research
* the incidence of adverse life events in the last 3 months
* use of medication (e.g. oral birth control pill,painkiller,antipsychotic tablets)
* participation in other sports programs
* congenital uterine anomalies
* any chronic disease (e.g. neurological, psychological disorders, endocrinological diseases)
Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games

Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.

Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. Our previous findings (see Publications) show that the adult amblyopic brain is still plastic and malleable, suggesting that active approach is potential useful in treating amblyopia.The goal of this project is to assess the limits and mechanisms of neural plasticity in both normal and amblyopic spatial vision. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia. Research participants will be asked to practice a visual discrimination task (perceptual learning) or to play video games with the amblyopic eye for a period of time. A range of visual functions will be monitored during the course of treatment.

Eligibility Criteria:
Inclusion Criteria:

* adults and children with normal vision or amblyopia
* amblyopia: interocular VA difference of 0.1 logMAR or more

Exclusion Criteria:

* any ocular pathological conditions, nystagmus
Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.

To prove the safety of the gynaecological formulation in normal conditions of use.


Eligibility Criteria:
Inclusion criteria:

* Integral skin test in the region;
* Use of cosmetic product of the same category;
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time;

Exclusion criteria:

* Lactation or gestational risk or gestation;
* Use of Anti-inflammatory, immunosuppression or antihistaminic drugs;
* Atopic antecedent or allergic to cosmetic product;
* Active cutaneous disease in the evaluation area;
* Diseases which cause immunology decrease, such as diabetes and HIV;
* Endocrinal pathologies;
* Intense solar exposure 15 days before the evaluation;
* Treatment until four months before the selection

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.


Eligibility Criteria:
Inclusion Criteria:

* Male and female children between 6 months and 4 years of age
* Weight does not exceed 40 kg
* Clinical diagnosis is acute otitis media
* Have evidence of middle ear fluid
* At risk for persistent or recurrent otitis media
* Generally in good health

Exclusion Criteria:

* Sensitivity or allergy to penicillins or cephalosporins or inability to take oral medications
* Presence of tympanostomy tubes, ventilation tube or perforated tympanic membrane, in either ear
* Treatment with any anti-infective agent within 3 days prior to the study or treatment with a long-acting injectable antimicrobial agent (e.g. , penicillin G benzathine) within 4 weeks prior to the study
* Concomitant infection, that requires additional antimicrobial therapy
* Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the patient's therapeutic response